T1	intervention 10 17	CYP19A1
T2	intervention 22 26	ESR1
T3	eligibility 653 716	premenopausal women with hormone-responsive early breast cancer
T4	duration 739 746	5-years
T8	outcome-Measure 1083 1209	Associations of the genotype variants with grade ≥2 early-onset targeted AEs of hot flashes/sweating or musculoskeletal events
T9	No-of-participants 1269 1273	2660
T10	No-of-participants 1366 1370	1967
T11	outcome 1505 1555	reduced incidence of grade ≥2 hot flashes/sweating
T12	outcome 1806 1883	No association with any of the CYP19A1/ESR1 genotypes and musculoskeletal AEs
